Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Graymatters Health Ltd |
| Country | Israel |
| Start Date | Sep 01, 2022 |
| End Date | May 31, 2025 |
| Duration | 1,003 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190165249 |
Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at 7.5B. Current treatments success is marginal, costly, with severe side-effects.
GrayMatters is the first to introduce a non-invasive digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity.
Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results.
The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.
Graymatters Health Ltd
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant